Skip to main content
RIGEL PHARMACEUTICALS INC logo

RIGEL PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · RIGL ISIN · US7665597024 LEI · 529900KPTNUS5J8K9K66 US Manufacturing
Filings indexed 1,024 across all filing types
Latest filing 2026-05-20 Regulatory Filings
Country US United States of America
Listing US RIGL

About RIGEL PHARMACEUTICALS INC

https://www.rigel.com/

Rigel Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, and provides novel small-molecule drugs. The company focuses on therapies for hematologic disorders, cancer, and rare immune diseases. Its portfolio of commercialized products includes TAVALISSE® (fostamatinib disodium hexahydrate) for the treatment of chronic immune thrombocytopenia, REZLIDHIA® (olutasidenib) for relapsed or refractory acute myeloid leukemia, and GAVRETO® (pralsetinib). In addition to its commercial products, Rigel maintains a clinical development pipeline investigating therapies such as IRAK1/4 and RIPK1 inhibitors for various inflammatory and immune conditions.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings
2026-05-20 English
DEF 14A - RIGEL PHARMACEUTICALS INC (0001034842) (Filer)
Proxy Solicitation & Information Statement
2026-04-03 English
SCHEDULE 13G/A - RIGEL PHARMACEUTICALS INC (0001034842) (Subject)
Major Shareholding Notification
2026-03-27 English
8-K - RIGEL PHARMACEUTICALS INC (0001034842) (Filer)
Regulatory Filings
2026-03-03 English
10-K - RIGEL PHARMACEUTICALS INC (0001034842) (Filer)
Annual Report FY 2025
2026-03-03 English
4 - RIGEL PHARMACEUTICALS INC (0001034842) (Filer)
Director's Dealing
2026-02-24 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.